Answers are grounded in this paper and cite their sources.
BACKGROUND & AIMS: The clinical benefit of bezafibrate (BZF) in primary biliary cholangitis (PBC) has not been extensively quantified using absolute measures. We assessed the number needed to treat (NNT) with BZF to prevent liver transplantation (LT) or death (including liver-related death) in patients with PBC. METHODS: ) was estimated. RESULTS: values were 10 (95% CI 7-18), 7 (95% CI 5-13), and 4 (95% CI 3-8). CONCLUSIONS: The projected efficacy of BZF, expressed as the NNT to prevent hard clinical endpoints, was substantial overall, including among patients with relatively favourable ALP levels (1.0-1.5 × ULN) after one year of UDCA treatment. These findings highlight the potential clinical benefit of off-label BZF in UDCA-treated patients without ALP normalisation. IMPACT AND IMPLICATIONS: Although infrequently used in hepatology, the number needed to treat (NNT) can increase awareness among clinicians and patients about the potential impact of second-line therapy. Bezafibrate showed strong efficacy (NNT <20) for preventing liver transplantation or (liver-related) death in people with primary biliary cholangitis, even in patients with relatively favourable alkaline phosphatase levels (1.0-1.5 × the upper limit of normal) after 1 year of ursodeoxycholic acid. Findings support the potential clinical benefit of off-label bezafibrate for patients who do not achieve alkaline phosphatase normalisation on ursodeoxycholic acid alone. The NNT facilitates shared decision-making between patients and physicians on the use of second-line therapy in people with primary biliary cholangitis.
No takes yet. Share an insight, caveat, or question.
Werner et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: